# Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

> **NCT05776069** · PHASE1,PHASE2 · RECRUITING · sponsor: **Vega Therapeutics, Inc** · enrollment: 116 (estimated)

## Conditions studied

- Von Willebrand Diseases

## Interventions

- **DRUG:** VGA039
- **OTHER:** Placebo
- **DRUG:** VGA039

## Key facts

- **NCT ID:** NCT05776069
- **Lead sponsor:** Vega Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05776069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05776069, "Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05776069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*